About WeSave
WeSave is a company seeking to develop an alternative early cancer diagnostics screening tool for people who do not show symptoms. We detect DNA cancer biomarkers through simple blood test to predict the likelihood of future cancers. The chances of cancer survival are 60% higher if detected at early stage. Our method is risk-free and painless as compared to conventional biopsy where doctors use needles to take out tissues from tumors for analysis. We provide on-site detection within a day whereas biopsy can take up to weeks. Our technique is already validated in our lab, and we have patented and published several peer-reviewed articles in prestigious scientific journals. We have two products, the main and the by-product of the manufacturing process. The main product is the kit containing the components needed for the detection of cancer and the by-product is the magnetic nanoparticles. Selling price for the kit is$400 and the total manufacturing cost is $100. Our customers are pathologists and research labs, and users are hospitals, doctors, and patients. We will make license agreement with our customers and train them for free as they buy our kits. We start generating revenue from day one to sustain the company by selling the by-product to research labs as the regulatory laws to sell that by-product is significantly lenient than our detection kit. We will run pilot test in blood samples of 300 patients in March 2024 in collaboration with Scientia clinical research and expect to hit the market at the end of 2024.
